8-K: Marinus Pharmaceuticals Wins Patent Challenge as PTAB Denies Ovid Therapeutics' Review Petition

Marinus Pharmaceuticals successfully defended its patent for ganaxolone in treating status epilepticus as the Patent Trial and Appeal Board denied Ovid Therapeutics' petition for Inter Partes Review.

Summary

• Marinus Pharmaceuticals faced a patent challenge from Ovid Therapeutics regarding the use of ganaxolone in treating status epilepticus.
• Ovid filed a petition for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) on March 26, 2024.
• Marinus responded to the petition on June 26, 2024.
• The PTAB denied Ovid's petition on September 20, 2024, stating that Ovid did not demonstrate a reasonable likelihood of proving the patent's unpatentability.
• Ovid has 30 days from September 20, 2024, to file for a rehearing or seek director review at the PTAB.
• Ovid cannot appeal the denial of the institution to the U.S. Court of Appeals for the Federal Circuit.

Sentiment

Score: 8

Explanation: The document conveys a positive outcome for Marinus Pharmaceuticals as they successfully defended their patent. The risk of patent invalidation has been reduced, which is a positive development for the company.

Positives

• Marinus Pharmaceuticals successfully defended its patent against a challenge from Ovid Therapeutics.
• The PTAB's decision supports the validity of Marinus' patent for ganaxolone in treating status epilepticus.
• The denial of the IPR petition reduces the risk of patent invalidation for Marinus.

Negatives

• Ovid Therapeutics still has the option to request a rehearing or seek director review at the PTAB, which could prolong the legal uncertainty.

Risks

• Ovid Therapeutics may file for a rehearing or seek director review at the PTAB, which could lead to further legal proceedings.
• The outcome of any potential rehearing or director review is uncertain.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• Steven Pfanstiel, Chief Operating Officer, Chief Financial Officer and Treasurer, signed the report on behalf of Marinus Pharmaceuticals.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies involved in developing treatments for neurological disorders. The outcome of patent challenges can significantly impact a company's competitive position and future revenue streams.

Comparison to Industry Standards

• Patent disputes are common in the pharmaceutical industry, especially for novel treatments.
• The denial of an IPR petition is a positive outcome for Marinus, as it indicates that the PTAB found Ovid's arguments unconvincing.
• Companies like Biogen, Amgen, and Gilead Sciences often face similar patent challenges, and the outcomes can have significant financial implications.

Legal Proceedings

• Ovid Therapeutics filed a petition for Inter Partes Review (IPR) of one of Marinus Pharmaceuticals' patents.
• The PTAB denied Ovid's petition.

Stakeholder Impact

• Shareholders of Marinus Pharmaceuticals are likely to view this as a positive development as it reduces the risk of patent invalidation.
• The outcome could positively impact the company's valuation.

Next Steps

• Ovid Therapeutics has 30 days from September 20, 2024, to file for a rehearing or seek director review at the PTAB.

Key Dates

Keywords

patent, ganaxolone, status epilepticus, Inter Partes Review, PTAB, Marinus Pharmaceuticals, Ovid Therapeutics, intellectual property